IDXX - Is There An Opportunity To Buy IDEXX Labs The Animal Diagnostics-Focused Firm Stock After Q3 Performance? Analyst Answers | Benzinga
IDEXX Laboratories Inc (NASDAQ: IDXX) reported Q3 FY23 sales of $915.53 million, missing the consensus of $926.76 million. Adjusted EPS was $2.50 versus the consensus of $2.37 and $2.15 a year ago.
The company reported an increase of 9% and 8% organic, driven by Companion Animal Group (CAG) growth of 9% reported and 8% organic and Water revenue growth of 9% reported and 7% organic.
Veterinary software, services, and diagnostic imaging systems revenue grew 14% as reported and 13% organically, reflecting high recurring revenue growth ...